Products
Pre-made Vatelizumab benchmark antibody ( Whole mAb, anti-ITGA2 therapeutic antibody, Anti-BR/CD49B/GPIa/HPA-5/VLA-2/VLAA2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-615
Pre-Made Vatelizumab biosimilar, Whole mAb, Anti-ITGA2 Antibody: Anti-BR/CD49B/GPIa/HPA-5/VLA-2/VLAA2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Vatelizumab is an immunomodulator. It binds to integrin alpha 2. It was withdrawn from Phase II trials for inflammatory bowel disease due to a lack of efficacy.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-615-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size： 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Vatelizumab biosimilar, Whole mAb, Anti-ITGA2 Antibody: Anti-BR/CD49B/GPIa/HPA-5/VLA-2/VLAA2 therapeutic antibody |
| INN Name | Vatelizumab |
| Target | ITGA2 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II/III |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2011 |
| Year Recommended | 2012 |
| Companies | Chromos Molecular Systems;Glenmark Pharmaceuticals S.A.;Sanofi |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Cancer;Chronic obstructive pulmonary disease;Multiple sclerosis;Retinal disorders;Rheumatoid arthritis;Ulcerative colitis |
| Development Tech | na |
<